Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibrutinib + idelalisib
- Development stage
- Preclinical
- Lead developer
- Pharmacyclics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy targeting different components of the B-cell receptor (BCR) signaling pathway. Ibrutinib is a covalent inhibitor of Bruton's tyrosine kinase (BTK), while idelalisib specifically inhibits the delta isoform of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3Kδ). The combination has shown synergistic effects in inhibiting BCR-controlled adhesion and potentially overcoming therapy resistance in B-cell malignancies.
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on ibrutinib + idelalisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibrutinib + idelalisib.